<SEC-DOCUMENT>0001193125-25-225853.txt : 20251001
<SEC-HEADER>0001193125-25-225853.hdr.sgml : 20251001
<ACCEPTANCE-DATETIME>20251001070621
ACCESSION NUMBER:		0001193125-25-225853
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250930
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251001
DATE AS OF CHANGE:		20251001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HALOZYME THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001159036
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				880488686
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32335
		FILM NUMBER:		251362548

	BUSINESS ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 794-8889

	MAIL ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HALOZYME THERAPEUTICS INC
		DATE OF NAME CHANGE:	20040312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL YACHT SERVICES INC
		DATE OF NAME CHANGE:	20010912
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d940775d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:halo="http://www.halozyme.com/20250930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-275">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-09-30_to_2025-09-30">0001159036</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="halo-20250930.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-09-30_to_2025-09-30"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-09-30</xbrli:startDate> <xbrli:endDate>2025-09-30</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-286">8-K</ix:nonNumeric></span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt:datemonthdayyearen" id="ixv-287">September&#160;30, 2025</ix:nonNumeric></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-288">HALOZYME THERAPEUTICS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Commission File Number <span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-289">001-32335</ix:nonNumeric></span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:stateprovnameen" id="ixv-290">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-291">88-0488686</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"></span><span style="font-style:italic">(State or other jurisdiction</span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><br/></span></span><span style="font-weight:bold"></span><span style="font-style:italic">of incorporation or organization)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"></span><span style="font-style:italic">(I.R.S. Employer</span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><br/></span></span><span style="font-weight:bold"></span><span style="font-style:italic">Identification No.)</span><span style="font-weight:bold"></span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-292">12390 El Camino Real</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-293">San Diego</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:stateprovnameen" id="ixv-294">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-295">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"></span><span style="font-style:italic">(Address of principal executive offices)</span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"></span><span style="font-style:italic">(Zip Code)</span><span style="font-weight:bold"></span></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-296">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-297">794-8889</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Registrant&#8217;s telephone number, including area code) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Former name or former address, if changed since last report) </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:boolballotbox" id="ixv-298">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:boolballotbox" id="ixv-299">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:boolballotbox" id="ixv-300">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:boolballotbox" id="ixv-301">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-302">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-303">HALO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:exchnameen" id="ixv-304">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-09-30_to_2025-09-30" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;1, 2025, Halozyme issued a press release announcing the execution of an Agreement and Plan of Merger, dated as of September&#160;30, 2025, by and among Elektrofi, Inc., a Delaware corporation, Halozyme Therapeutics, Inc., a Delaware corporation, Erraid Merger Sub Inc., a Delaware corporation, and Shareholder Representative Services LLC, a Colorado limited liability company (the &#8220;<span style="text-decoration:underline">Press Release</span>&#8221;). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under this Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d940775dex991.htm">Press Release of Halozyme Therapeutics, Inc., dated as of October&#160;1, 2025 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">HALOZYME THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:18pt"/>
<td style="height:18pt" colspan="2"/>
<td style="height:18pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">October&#160;1, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <span style="font-style:italic"></span>Nicole LaBrosse</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Nicole LaBrosse</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Senior Vice President, Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d940775dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Drug Delivery and Strengthening Long-Term Growth into 2040s </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Royalty revenue contribution expected to begin as early as 2030 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Initial partner targets include derisked MoAs that are approved blockbusters today </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Highly scalable licensing model and</I><B><I> </I></B><I>long duration IP into 2040s; potential for individual </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>product IP extension through proprietary reformulation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Two of Elektrofi&#8217;s partners projected to begin Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> formulated product clinical
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>development by year end 2026, or earlier </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">SAN DIEGO, October&nbsp;1, 2025 / PRNewswire / &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced it has entered into a
definitive agreement to acquire Elektrofi, Inc. (&#8220;Elektrofi&#8221;), a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded
Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. The transaction, which is comprised of an upfront payment of $750&nbsp;million and up to three $50&nbsp;million milestone payments contingent on three separate product regulatory
approvals, was unanimously approved by the Boards of Directors of both Halozyme and Elektrofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The
Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology is an innovative microparticle approach that sets a new standard in the pursuit of hyper concentration, enabling high protein concentrations while maintaining
syringeability, which is the ability to inject smoothly and easily. Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> enables biologic product formulation concentrations of <FONT STYLE="white-space:nowrap">400-500</FONT> mg/ml,
which can be up to 4 to 5 times higher than standard aqueous solution formulations for biologics today. The increased concentration reduces the volume of injection for the same dosage and will create more opportunities for <FONT
STYLE="white-space:nowrap">at-home</FONT> and HCP office delivery, including via small volume auto-injector or with Halozyme&#8217;s innovative high volume auto-injector. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&#8220;This acquisition marks a pivotal step in Halozyme&#8217;s evolution. With Elektrofi&#8217;s Hypercon technology, we are expanding and diversifying our drug
delivery technology offerings to the biopharma industry and positioning Halozyme for continued long-term revenue growth through Elektrofi&#8217;s licensing, royalty revenue business model,&#8221; said Dr.&nbsp;Helen Torley, President and Chief
Executive Officer of Halozyme. &#8220;We look forward to welcoming Elektrofi&#8217;s talented team as we embark on our next chapter of drug delivery innovation to continue to drive value for all of our stakeholders including our partners, patients,
and shareholders.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Chase Coffman, Chief Executive Officer and Co-founder of Elektrofi, commented, &#8220;Since Elektrofi&#8217;s founding, we have been
committed to revolutionizing the delivery of biologic therapies so that patients can live life on their terms. Today&#8217;s announcement brings us closer to achieving that vision. Halozyme&#8217;s proven industry expertise and capabilities in
developing drug delivery licensing businesses will advance our unique Hypercon technology, strengthen existing collaborations, support expansion into new partnerships and accelerate our commercialization strategy.&#8221; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compelling Strategic Rationale </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Strong Strategic Fit: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Extends Halozyme&#8217;s vision and breadth of innovative drug delivery technologies </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Setting new standards in convenience, accessibility and treatment options with broad portfolio of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-market</FONT></FONT> proprietary technologies </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Complementary SC technologies support secular trend toward <FONT STYLE="white-space:nowrap">at-home</FONT> and in
healthcare practitioner office administration of biologics </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology substantially expands scope of therapeutics
that can be delivered subcutaneously with its ability to deliver highly concentrated biologics subcutaneously </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Highly scalable licensing model with compelling expansion opportunities </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Broad range of biologics programs and modalities creates meaningful opportunities across existing and new partners
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Well aligned business models with royalty revenue and low capital intensity </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Long duration intellectual property into 2040s </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Supports long-term revenue growth opportunity </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Enhances durability of drug delivery licensing business model </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Poised for Growth: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Expect near-term inflection and value creation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Initial partner products include <FONT STYLE="white-space:nowrap">de-risked</FONT> MoAs that are approved blockbusters
today </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Two of Elektrofi&#8217;s partners projected to begin Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
formulated product clinical development by year end 2026, or earlier </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Clear pathway for significant growth beginning as early as 2030 </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Royalty revenues are projected to begin in 2030 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Up to $275&nbsp;million in potential development and commercial milestone payments from Elektrofi&#8217;s existing two
partner products expected to enter clinical development by year end 2026, or earlier, supports near-term <FONT STYLE="white-space:nowrap">de-risking</FONT> of acquisition and low capital intensity of Elektrofi </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Acquisition supports further <FONT STYLE="white-space:nowrap">de-risking</FONT> and accelerated commercialization
timeline of Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Leverages Halozyme&#8217;s proven track record of developing, commercializing and scaling SC drug delivery technologies
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Financial Update </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The transaction is expected to be
less than 5% dilutive to <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> diluted EPS over medium-term, excluding potential milestone payments related to programs in development, which could offset dilution prior to projected royalty revenue in 2030
and beyond. We expect full year 2026 incremental operating expense of approximately $55&nbsp;million. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Today, Halozyme is reaffirming its 2025 guidance ranges, which were last updated on August 5<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>, 2025, excluding the impact of the accounting treatment of the transaction. The final determination of whether this transaction will be accounted for as a business combination or asset acquisition
will be determined at the close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">For the full year 2025, the Company expects: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Total revenue of $1,275&nbsp;million to $1,355&nbsp;million, representing growth of 26% to 33% over 2024 total revenue,
primarily driven by increases in royalty revenue. Revenue from royalties of $825&nbsp;million to $860&nbsp;million, representing growth of 44% to 51% over 2024. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> of $865&nbsp;million to $915&nbsp;million,
representing growth of 37% to 45% over 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> diluted earnings per
share<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> of $6.00 to $6.40, representing growth of 42% to 51% over 2024. The Company&#8217;s earnings per share guidance does not consider the impact of potential future share repurchases.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Table 1. 2025 Financial Guidance </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Guidance Range</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$1,275&nbsp;to&nbsp;$1,355&nbsp;million</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Royalty Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$825 to $860&nbsp;million</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top"> 1</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$865 to $915&nbsp;million</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Diluted
EPS<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$6.00 to $6.40</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transaction Details </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Under the terms of the
agreement, Halozyme will acquire Elektrofi for $750&nbsp;million in upfront consideration, financed by the Company&#8217;s existing cash on its balance sheet and existing credit facility. The remaining consideration amount will be payable based on
three contingent milestones for the successful marketing approvals of three Hypercon<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> products, valued at $50&nbsp;million each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Company expects its net leverage to be increased to approximately 2X net
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debt-to-EBITDA</FONT></FONT><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> immediately following the transaction close and expects to rapidly
<FONT STYLE="white-space:nowrap">de-lever</FONT> in the subsequent quarters. The transaction is expected to close in 4Q 2025, subject to completion of HSR review and other customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">BofA Securities, Inc. is acting as financial advisor to Halozyme and Weil, Gotshal&nbsp;&amp; Manges LLP is acting as legal advisor. Centerview Partners LLC is acting
as financial advisor to Elektrofi and Morgan, Lewis&nbsp;&amp; Bockius LLP is acting as legal advisor. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Adjusted EBITDA and <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Diluted EPS are
<FONT STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures. See &#8220;Note Regarding Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures&#8221; below for an explanation of these measures. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conference Call Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Halozyme will host a conference call and webcast today, Wednesday, October&nbsp;1 at 5:30am PT/8:30am ET. The conference call may be accessed live with <FONT
STYLE="white-space:nowrap">pre-registration</FONT> via link: https://registrations.events/direct/Q4I781370. The call will also be webcast live through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website and a recording will be
made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Halozyme
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As
the innovators of ENHANZE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially-validated solution is used to facilitate the subcutaneous delivery of
injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one
major region and across more than 100 global markets, Halozyme has licensed its ENHANZE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer,
Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Halozyme also develops, manufactures
and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and
tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and XYOSTED<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">For more information visit&nbsp;<U>www.halozyme.com</U>&nbsp;and connect with us on LinkedIn and Twitter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Elektrofi </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Elektrofi is a biopharmaceutical formulation technology
company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Its breakthrough hyper concentrated microparticle technology, Hypercon<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient <FONT STYLE="white-space:nowrap">at-home</FONT> subcutaneous self-administration. With a
focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, they create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. Elektrofi believes a patient-centered healthcare
approach can lead to a healthier world. The company is headquartered in Boston and innovates globally. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Note Regarding Use of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In this press release we provide guidance with respect to measures not considered to be in accordance with generally accepted accounting principles <FONT
STYLE="white-space:nowrap">(&#8220;Non-GAAP&#8221;)</FONT> measures, such as adjusted earnings before interest, taxes, depreciation, and amortization (&#8220;Adjusted EBITDA&#8221;) and <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> diluted
earnings per share. These measures are in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company calculates <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> diluted earnings per
share excluding share-based compensation expense, amortization of debt discounts, intangible asset amortization, <FONT STYLE="white-space:nowrap">one-time</FONT> items, if any, such as changes in contingent liabilities, inventory adjustments,
impairment charges and intellectual property litigation costs, and certain adjustments to income tax expense. The Company calculates <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> diluted shares excluding the dilutive impact of convertible notes
which is used in calculating <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> diluted earnings. The Company calculates EBITDA excluding interest, taxes, depreciation and amortization. The Company calculates adjusted EBITDA excluding <FONT
STYLE="white-space:nowrap">one-time</FONT> items, if any, such as changes in contingent liabilities, inventory adjustments, impairment charges, transaction costs for business combinations and intellectual property litigation costs. The Company does
not provide reconciliations of forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes
in share-based compensation expense and the effects of any discrete income tax items. For the same reasons, the Company is unable to address the probable significance of the unavailable information. The Company provides <FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> financial measures that it believes will be achieved; however, it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the <FONT
STYLE="white-space:nowrap">Non-GAAP</FONT> measures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements
concerning the Company&#8217;s expected future financial performance and growth rates (including the Company&#8217;s 2025 financial guidance and the assumptions used in deriving such guidance) including expectations for future total revenues,
collaboration and royalty revenues, adjusted EBITDA and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> diluted EPS, future plans, objectives, expectations and intentions relating to a potential transaction concerning Elektrofi, such potential
transaction&#8217;s expected impact and contributions to the Company&#8217;s, Elektrofi&#8217;s and the combined group&#8217;s operations and financial results (including potential development and commercialization of partnered products and timing
related to these events), the financing and closing of such potential transaction, as well as the expected timing and benefits of such potential transaction, the Company&#8217;s and Elektrofi&#8217;s future product development and regulatory events
and goals, and product collaborations. Forward-looking statements regarding the Company&#8217;s ENHANZE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> drug delivery technology include the possible benefits and attributes of ENHANZE<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> including its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of
injectable medications through subcutaneous delivery and potential to decrease treatment burden and enable new treatment sites. Forward-looking statements regarding Elektrofi&#8217;s
Hypercon<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology include statements regarding its ability to achieve certain levels of biologic concentration and enable the administration of smaller volumes or doses of pharmaceutical
products. Forward-looking statements related to Elektrofi&#8217;s intellectual property include expectations for length of patent terms and patent expirations and the expected impact such patents may have on the duration, durability and amounts of
future royalty payments the Company may receive from licensing such intellectual property. Forward-looking statements regarding the combined group&#8217;s business may also include potential growth driven by the combined group&#8217;s partner
development and commercialization efforts (including anticipated product approvals and launches and the timing related to these events), anticipated royalty terms and rates for the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Company&#8217;s current and future collaboration products and product candidates, projections for future sales revenue and market share of the combined group&#8217;s collaborators&#8217; products
and product candidates, potential new or expanded collaborations, collaborative targets and indications for partnered products. These forward-looking statements are typically, but not always, identified through use of the words &#8220;expect,&#8221;
&#8220;believe,&#8221; &#8220;enable,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;durable,&#8221; &#8220;growth,&#8221; &#8220;innovate,&#8221; &#8220;develop,&#8221; &#8220;vision,&#8221;
&#8220;potential,&#8221; &#8220;intends,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;probable,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;should,&#8221;
&#8220;continue,&#8221; and other words of similar meaning and involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the
expectations contained in these forward-looking statements as a result of several factors, including uncertainties concerning future matters such as market conditions, changes in domestic and foreign business, changes in the competitive environment
in which the Company and Elektrofi operate, and financing a potential transaction, inability of the parties to successfully or timely consummate a transaction, including the risk that any required regulatory approvals are not obtained, are delayed
or are subject to unanticipated conditions that could adversely affect the combined group or the expected benefits of a transaction, unexpected levels of the combined group&#8217;s revenues, expenditures and costs, unexpected results or delays in
the growth of the combined group&#8217;s business, or in the development, regulatory review or commercialization of the combined group&#8217;s partnered or proprietary products, unexpected early expiration or termination of the patent terms for the
combined group&#8217;s drug delivery technologies, unexpected levels of revenues (including royalty revenue received from the combined group&#8217;s collaboration partners and revenues from proprietary product sales), expenditures and costs,
unexpected results or delays in the growth of the combined group&#8217;s business (including as a result of unexpected conversion rates) or other proprietary product revenues, or in the development, regulatory review or commercialization of the
combined group&#8217;s partnered products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the
Company&#8217;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission, including under the headings
&#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking
statements or any other information contained herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Tram Bui
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Halozyme </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">609-359-3016</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>tbui@halozyme.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>halo-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/1/2025 2:34:50 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:halo="http://www.halozyme.com/20250930"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.halozyme.com/20250930"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>halo-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/1/2025 2:34:50 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>halo-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/1/2025 2:34:50 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="halo-20250930.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001159036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HALOZYME THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0488686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12390 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">794-8889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HALO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d940775d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d940775d8k.htm">d940775d8k.htm</File>
    <File>halo-20250930.xsd</File>
    <File>halo-20250930_lab.xml</File>
    <File>halo-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d940775d8k.htm": {
   "nsprefix": "halo",
   "nsuri": "http://www.halozyme.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "d940775d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "halo-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "halo-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "halo-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-09-30_to_2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d940775d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-09-30_to_2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d940775d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.halozyme.com//20250930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-25-225853-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-225853-xbrl.zip
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MJE0BD=LDZS>FV9LCD*0HB.; 0GL\@&J'ZNB=1%,9W^@,KX$0BRR#(9CP"<@
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MU@W4%J2NW:$'D3X=8KK91$/A[14<!D(9!:N% A%^5ZG#(,SI8DB#'9D(+JJ
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M-9@KN"!7\K,3\#(I<MD=@7K#Q<.UM:IJK".0?8GR ?JN4-$HS9)L."-5!<^
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M^WKC?O2^>D7T;F\&]*ZO7,"5C%@9Z<7_P=TL@%C[)]>'O0<Z8)O6]R(^?;V
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MO@YY/?-RUC!=:&^>-6)_'43B#E4A=6*>+VC_,77PD3I#V1!BN^5[B@;!46[
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MA*%1PO\#_('*R>9ZVP8XU/V>TNW 6HEADO6E\UA-X-?C\2)<"D['C9@GX)>
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M EQX?OAO^/+X^L/IWO\"4$L#!!0    ( ,HX05N*%1,G/ ,  $H+   1
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M[\"=QC[@=KD.1]XSVXWK;ON"]6/,MN>XNQG.>WO5[AOZ^2]02P,$%     @
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M4$L! A0#%     @ RCA!6\J+U4?;#P   F4   X              ( !
M &0Y-# W-S5D.&LN:'1M4$L! A0#%     @ RCA!6T5N.ZF*(   GY\  !$
M             ( !!Q   &0Y-# W-S5D97@Y.3$N:'1M4$L! A0#%     @
MRCA!6XH5$R<\ P  2@L  !$              ( !P#   &AA;&\M,C R-3 Y
M,S N>'-D4$L! A0#%     @ RCA!6]R+=VE<!@  O$,  !4
M ( !*S0  &AA;&\M,C R-3 Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( ,HX05M[
M88$>M00  'HJ   5              "  ;HZ  !H86QO+3(P,C4P.3,P7W!R
;92YX;6Q02P4&      4 !0!  0  HC\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>d940775d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="halo-20250930.xsd" xlink:type="simple"/>
    <context id="duration_2025-09-30_to_2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-275">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-09-30_to_2025-09-30"
      id="Hidden_dei_EntityCentralIndexKey">0001159036</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-286">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-287">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-288">HALOZYME THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-289">001-32335</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-290">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-291">88-0488686</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-292">12390 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-293">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-294">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-295">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-296">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-297">794-8889</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-298">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-299">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-300">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-301">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-302">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-303">HALO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-304">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-09-30_to_2025-09-30" id="ixv-305">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
